MedTrace Logo

THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy

NCT06859710 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-12-17

No results posted yet for this study

Summary

The purpose of this research is to assess the impact of CBD on the effects of THC.

Conditions

Interventions

DRUG

CBD 80 mg

Vaporized CBD (80 mg)

DRUG

Placebo

Vaporized Placebo

DRUG

THC

Vaporized THC (20 mg)

DRUG

CBD 20 mg

Vaporized CBD (20 mg)

DRUG

CBD 40 mg

Vaporized CBD (40 mg)

Sponsors & Collaborators

Principal Investigators

  • Ziva Cooper, PhD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-05
Primary Completion
2027-09-01
Completion
2028-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06859710 on ClinicalTrials.gov